Mechanisms of Hypocholesterolemia

  • C. L. Malmendier
  • J.-F. Lontie
  • D. Y. Dubois
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 285)


Although clinically significant hypocholesterolemia occurs less frequently than hypercholesterolemia, it has usually important conse quences that involve derangement of major metabolic roles of lipoproteins.


Visceral Leishmaniasis Trypanosoma Brucei Myeloproliferative Disease Acute Myelogenous Leukemia Cell Tangier Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. The Lipid Research Clinics Program Epidemiology Committee: Plasma lipid distributions in selected north american populations: the lipid research clinics program prevalence study. Circulation., 60:427 (1979).Google Scholar
  2. 2.
    B. V. Howard, M. P. Davis, D. J. Pettitt, W. C. Knowler, and P. H. Bennett, Plasma and lipoprotein cholesterol and triglyceride concentrations in the Pima Indians: distributions differing from those of Caucasians, Circulation, 68:714 (1983).PubMedCrossRefGoogle Scholar
  3. 3.
    W. J. McConathy and D. M. Lane, Studies on the apolipoproteins and lipoproteins of cord serum, Pediat. Res., 14:757 (1980).PubMedCrossRefGoogle Scholar
  4. 4.
    B. Christensen, C. Glueck, P. Kwiterovich, I. Degroot, G. Chase, G. Heiss, R. Mowery, I. Tamir, and B. Rifkind, Plasma cholesterol and triglyceride distributions in 13,665 children and adolescents: the Prevalence study of the lipid research clinics program, Pediat. Res.,14:194 (1980).PubMedCrossRefGoogle Scholar
  5. 5.
    H. A. Tyroler, C. J. Glueck, B. Christensen, and P. O. Kwiterovich, Plasma high-density lipoprotein cholesterol comparisons in black and white populations. The Lipid research clinics program prevalence study, Circulation, 62, IV–99 (1980).Google Scholar
  6. 6.
    W. E. Connor, M. T. Cequeira, R. U. Connor, R. B. Wallace, R. Malinow, and H. R. Casdorph, The plasma lipids, lipoproteins and diet of the Tarahumara Indians of Mexico, Am. J. Clin. Nutr., 31–1131 (1978).Google Scholar
  7. 7.
    J. Burslem, G. Schonfeld, M. A. Howald, S. W. Weidman, and J. P. Miller, Plasma apoprotein and lipoprotein lipid levels in vegetarians, Metabolism, 27:711 (1978).PubMedCrossRefGoogle Scholar
  8. 8.
    F. M. Sacks, D. Ornish, B. Rosner, S. McLanahan, W. P. Castelli, and E. H. Kass, Plasma lipoprotein levels in vegetarians. The effect of ingestion of fats from dairy products, J.A.M.A., 254:1337 (1985).PubMedCrossRefGoogle Scholar
  9. 9.
    E. J. Schaefer, R. I. Levy, N. D. Ernst, F. D. Van Sant, and H. B. Brewer, Jr., The effects of low cholesterol, high polyunsaturated fat, and low fat diets on plasma lipid and lipoprotein cholesterol levels in normal and hypercholesterolemic subjects, Am. J. Clin. Nutr., 34:1758 (1981).PubMedGoogle Scholar
  10. 10.
    L. A. Carlson and B. Philipson, Fish-eye disease, a new familial condition with massive corneal opacities and dyslipoproteinemia, Lancet, ii:921 (1979).CrossRefGoogle Scholar
  11. 11.
    G. Franceschini, C. Sirtori, A. Capurso, K. H. Weisgraber, and R. W. Mahley, A-I Milano apoprotein, J. Clin. Invest., 66:892 (1980).PubMedCrossRefGoogle Scholar
  12. 12.
    E. Gjone, Familial LCAT deficiency, Acta. Med. Scand., 194:353 (1973).PubMedCrossRefGoogle Scholar
  13. 13.
    P. Alaupovic, E.J. Schaefer, W. J. McConathy, J. D. Fesmire, and H. B. Brewer, Jr., Plasma apolipoprotein concentrations in familial apolipoprotein A-I and A-II deficiency (Tangier disease), Metabolism, 30:805 (1981).PubMedCrossRefGoogle Scholar
  14. 14.
    E. J. Schaefer, W. H. Heaton, M. G. Wetzel, and H. B. Brewer, Jr., Plasma apolipoprotein A-I absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease, Arteriosclerosis, 2:16 (1982).PubMedCrossRefGoogle Scholar
  15. 15.
    D. R. Illingworth, W. E. Connor, and P. Alaupovic, High density lipo protein metabolism in a patient with abetalipoproteinemia, Ann. Nutr. Metab., 25:1 (1981).PubMedCrossRefGoogle Scholar
  16. 16.
    J -F. Lontie, C. L. Malmendier, C. Sérougne, D. Y. Dubois, C. Dachet, J. Férézou, and D. Mathé, Plasma lipids, lipoproteins and apolipoproteins in two kindreds of hypobetalipoproteinemia, Atherosclerosis, 1990. To be published.Google Scholar
  17. 17.
    C. L. Malmendier, J -F. Lontie, C. Delcroix, C. Sérougne, J. Férézou, and L. M. Veiga, Low density lipoprotein metabolism in a kindred with familial hypobetalipoproteinemia, Submitted to Metabolism, 1990.Google Scholar
  18. 18.
    C. L. Malmendier, C. Delcroix, J -F. Lontie, D. Y. Dubois, Apolipoprotein C-II and C-III metabolism in a kindred of familial hypobetalipoproteinemia, Submitted to Metabolism, 1990.Google Scholar
  19. 19.
    T. Magot, K. Ouguerram, J -F. Lontie, and C. L. Malmendier, In vivo study of lipoprotein cholesteryl ester movements between plasma lipoproteins in familial hypobetalipoproteinemia, Congrés du Gerli, Nice, April 1990.Google Scholar
  20. 20.
    A. L. Truswell, J. D. L. Hansen, C. E. Watson, and P. Uannenburg, Relation of serum lipids and lipoproteins to fatty liver in kwashiorkor, Am. J. Clin. Nutr., 22:568 (1969).PubMedGoogle Scholar
  21. 21.
    D. Lemonnier and Y. Ingenbleek, Les carences nutritionnelies dans les pays du Tiers Monde, GERM, Paris, Karthala-ACCT (1990)Google Scholar
  22. 22.
    D. Bekaert, R. Kallel, M -E. Bouma, J -F. Lontie, A. Mebazaa, C. L. Malmendier, and M. Ayrault-Jarrier, Plasma lipoproteins in infantile visceral leishmaniasis: deficiency of apolipoproteins A-I and A-II, Clin. Chim. Acta, 184:181 (1989).PubMedCrossRefGoogle Scholar
  23. 23.
    C. A. Rouzer and A. Cerami, Hypertriglyceridemia associated with Trypanosoma brucei infection in rabbits: role of defective triglyceride removal, Mol. Biochem. Parasitol., 2:31 (1980).PubMedCrossRefGoogle Scholar
  24. 24.
    B. Beutler and A. Cerami, Tumor necrosis, cachexia, shock, and inflammation: a common mediator, Ann. Rev. Biochem., 57:505 (1988).PubMedCrossRefGoogle Scholar
  25. 25.
    P. Scuderi, K. E. Sterling, K. S. Lam, P. R. Finley, K. J. Ryan, C. G. Ray, E. Petersen, D. J. Slymen, and S. E. Salmon, Raised serum levels of tumor necrosis factor in parasitic infections, Lancet, ii:1364 (1986).CrossRefGoogle Scholar
  26. 26.
    G. Assman, D. Fredrickson, P. Herbert, T. Forte, R. Heinen, An A-II lipoprotein particle in Tangier disease, Circulation, 50:259 (1974).Google Scholar
  27. 27.
    W. März and W. Gross, Immunochemical evidence for the presence in human plasma of lipoproteins with apolipoprotein A-II as the major protein constituant, Biochem. Biophys. Acta, 962:155 (1988).PubMedGoogle Scholar
  28. 28.
    M. R. Rifkin, Interaction of high-density lipoprotein with trypanosoma brucei: effect of membrane stabilizers, J. Cell. Biochem., 23:57 (1983).PubMedCrossRefGoogle Scholar
  29. 29.
    B. Galvao-Castro, J. A. Sa Ferreira, K. F. Marzochi, M. C. Marzochi, S. G. Coutinho, and P. H. Lambert, Polyclonal B-cell activation, circulating immune complexes and autoimmunity in human visceral leishmaniasis, Clin. Exp. Immunol., 56:58 (1984).PubMedGoogle Scholar
  30. 30.
    B. M. Rifkind and M. Gale, Hypolipidaemia in anaemia, Lancet, ii:640 (1967).CrossRefGoogle Scholar
  31. 31.
    H. S. Gilbert, H. Ginsberg, R. Fagerstrom, and W. V. Brown, Characterization of hypocholesterolemia in myeloproliferative disease. Relation to disease manifestations and activity, Am. J. Med., 71:595 (1981).PubMedCrossRefGoogle Scholar
  32. 32.
    R. E. Bases and I. H. Krakoff, Studies of serum cholesterol levels in leukemia, J. Reticuloendoth. Soc, 2:8 (1965).Google Scholar
  33. 33.
    Y. K. Ho, R. G. Smith, M. S. Brown, and J. L. Goldstein, Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells, Blood, 52:1099 (1978).PubMedGoogle Scholar
  34. 34.
    H. Ginsberg, H. S. Gilbert, J. C. Gibson, N -A. Le, and W. V. Brown, Increased low-density-lipoprotein catabolism in myeloproliferative disorders, Ann. Intern. Med., 96:311 (1982).PubMedGoogle Scholar
  35. 35.
    S. Vitols, M. Björkholm, G. Gahrtob, and C. Peterson, Hypocholesterolaemia in malignancy due to elevated low-densitylipoprotein-receptor activity in tumor cells: evidence from studies in patients with leukaemia, Lancet, i:1150 (1989).Google Scholar
  36. 36.
    U. E. Nydegger and R. E. Butler, Serum lipoprotein levels in patientswith cancer, Cancer Res., 32:1756 (1972).PubMedGoogle Scholar
  37. J -F. Lontie and C. L. Malmendier, unpublished observations.Google Scholar
  38. 38.
    C. L. Malmendier, J -F. Lontie, J. P. Soulier, and D. Y. Dubois, Modifications of plasma lipids, lipoproteins and apolipoproteins in advanced cancer patients treated with recombinant interleukin-2 and autologous lymphokine-activated killer cells, Atherosclerosis, 73:173 (1988).PubMedCrossRefGoogle Scholar
  39. 39.
    S. A. Rosenberg, M. T. Lotze, L. M. Muul, S. Leitman, A. E. Chang, S. E. Ettinghausen, Y. L. Matory, J. M. Skibber, E. Shiloni, J. T. Vetto, C. A. Seipp, C. Simpson, and C. M. Reichert, Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer, N. Engl. J. Med., 313:1485 (1985).PubMedCrossRefGoogle Scholar
  40. 40.
    J. A. Cuthbert and P. E. Lipski, Promotion of human T lymphocyte activation and proliferation by fatty acids in low density and high density lipoproteins, Proc. Natl. Acad. Sci. USA, 81:4539 (1984).PubMedCrossRefGoogle Scholar
  41. 41.
    M. T. Lotze, Y.L. Matory, S.E. Ettinghausen, A.A. Rainer, S. 0. Sharrow, C. A. Y. Seipp, M. C. Custer, and S. A. Rosenberg, In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL2, J. Immunol., 135:2865 (1985).PubMedGoogle Scholar
  42. 42.
    D. E. Wilson, G. R. Birchfield, J. S. Hejazi, J. P. Ward, and W. E. Samlowski, Hypocholesterolemia in patients treated with recombinant interleukin-2: appearance of remnant-like lipoproteins, J. Clin. Oncol., 7:1573 (1989)PubMedGoogle Scholar
  43. 43.
    M. L. Sherman, D. R. Spriggs, K. A. Arthur, K. Imamura, E. Frei III, and D. W. Kufe, Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: Phase I toxicity and effects on lipid metabolism, J. Clin. Oncol., 6:344 (1988).PubMedGoogle Scholar
  44. 44.
    S. D. Nimer, R. E. Champlin, and D. W. Golde, Serum cholesterol-lowering activity of granulocyte-macrophage colony-stimulating factor, JAMA, 260:3297 (1988).PubMedCrossRefGoogle Scholar
  45. 45.
    C. Ehnholm, K. Aho, J. K. Huttunen, E. Kostiainen, K. Mattila, J. Pikkarainen, and K. Cantell, Effect of interferon on plasma lipoproteins and on the activity of postheparin plasma lipases, Arteriosclerosis, 2:68 (1982).PubMedCrossRefGoogle Scholar
  46. 46.
    I. B. Rosenzweig, D. A. Wiebe, E. C. Borden, B. Storer, and E. S. Shrago, Plasma lipoprotein changes in humans induced by ß-interferon, Atherosclerosis, 67:261 (1987).PubMedCrossRefGoogle Scholar
  47. 47.
    R. Kurzrock, M. F. Rohde, J. R. Quesada, S. H. Gianturco, W. A. Bradley, S. A. Sherwin, and J. U. Gutterman, Recombinant ß interferon induces hypertriglyceridemia and inhibits post-heparin lipase activity in cancer patients, J. Exp. Med., 164:1093 (1986).PubMedCrossRefGoogle Scholar
  48. C. L. Malmendier, J -F. Lontie, D. Y. Dubois, and D. Math6, Lipids and apolipoproteins in liver transplanted patients, In preparation.Google Scholar
  49. 49.
    C. J. Glueck, P. Gartside, R. W. Fallat, J. Sielski, and P.M. Steiner, Longevity syndromes: familial hypobeta and familial hyperalphalipoproteinemia, J. Lab. Clin. Med., 88:941 (1976).PubMedGoogle Scholar
  50. 50.
    M. S. Brown and J.L. Goldstein, A receptor-mediated pathway for cholesterol homeostasis, Science, 232:34 (1986).PubMedCrossRefGoogle Scholar
  51. 51.
    C. B. Blum, R. J. Deckelbaum, L. D. Witte, A. R. Tall, and J. Cornicelli, Role of apolipoprotein E-containing lipoproteins in abetalipoproteinemia, J. Clin. Invest., 70:1157 (1982).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • C. L. Malmendier
    • 1
  • J.-F. Lontie
    • 1
  • D. Y. Dubois
    • 1
  1. 1.Fondation de Recherche sur l’AthéroscléroseBrusselsBelgium

Personalised recommendations